Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

0.5352 +0.0052 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Earnings Preview For Lexicon Pharmaceuticals
Via Benzinga
Lexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia Study
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced the topline results of RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia, a lasting pain in the areas of the skin that... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Micron, Lexicon Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Westrock Coffee Company, LLC (NASDAQ: WEST) shares tumbled 10.9% to $11.90... 
Via Benzinga
Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares rose 77.7% to $0.0906 in pre-market trading. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Lexicon Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study
Via Benzinga
Earnings Outlook For Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
Recap: Lexicon Pharmaceuticals Q2 Earnings
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lexicon... 
Via Benzinga
More Than $40 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
U.S. gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Financial Services Is Trading Higher By Over 217%; Here Are 38 Stocks Moving Premarket
Gainers AMTD IDEA Group (NYSE: AMTD) rose 217.3% to $6.60 in pre-market trading after jumping 18% on Monday. The company owns 90%+ of AMTD Digital. 
Via Benzinga
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
Lexicon Pharmaceuticals Earnings Preview
Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,... 
Via Benzinga
Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! It's time for another dive into the biggest pre-market stock movers as we check out what's happening Thursday morning! 
Via InvestorPlace
Why Meta Platforms Is Trading Lower By More Than 6%: Here Are 34 Stocks Moving Premarket
Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported better-than-expected Q2 results. 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
FDA Accepts Lexicon's New Drug Application For Review In Heart Failure Setting
The U.S. Food and Drug Administration (FDA) has accepted for review Lexicon Pharmaceuticals ‘ (NASDAQ: LXRX) New Drug Application (NDA) for sotagliflozin for the treatment of heart failure. The... 
Via Benzinga
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday! 
Via InvestorPlace
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.